• About what regulatory science and innovation is
• Understood why regulatory endorsement matters for project outputs
• Learned about the importance of defining a regulatory strategy from the outset
• Found out about the support services offered by the European Medicines Agency (EMA) for applicants and consortia
• Gained insights from lessons learned by other previous IMI projects that have successfully navigated regulatory processes
• Saw how maximising regulatory impact can benefit your project and consortium, and beyond.

Gill Farrar was invited to present the AMYPAD project and to highlight the regulatory value that the AMYPAD Biomarker Qualification Opinion (BQO) brought to the amyloid PET field.

You can find the recording of the session here: https://www.ihi.europa.eu/news-events/events/regulatory-impact-what-it-and-how-achieve-it-your-ihi-project